Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Status:
Completed
Trial end date:
2015-05-12
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg,
administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600
mutated advanced/metastatic melanoma.